Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for Postoperative Atrial Fibrillation in CABG
NCT05891145Recruiting
- Sponsor
- Yangzhou University
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of remimazolam in Atrial fibrillation (AFib) (2 arms), sponsored by Yangzhou University. Primary endpoint: Postoperative Atrial Fibrillation at 7 days. Started Feb 2023; status: recruiting.
02
Drugs
remimazolam
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05891145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891145.